Bioglutide (NA-931): Molecular Structure

Molecular Structure and Properties#

Bioglutide (NA-931) is a small synthetic molecule developed by Biomed Industries, Inc. Unlike conventional incretin-based therapies (semaglutide, tirzepatide, retatrutide) which are large peptides requiring injection, Bioglutide is a small molecule designed for oral administration. Its molecular structure has not been fully disclosed publicly, but available information indicates it is derived from a cyclic IGF-1 metabolite fragment.

The compound is described as a potent agonist at all four target receptors (IGF-1R, GLP-1R, GIPR, GCGR) at nanomolar concentrations, though specific binding affinity data (Ki or EC50 values) have not been published as of early 2026.

Structural Origin and Design#

Derivation from IGF-1#

Bioglutide is derived from a small cyclic fragment of insulin-like growth factor-1 (IGF-1). Specifically, it is described as comparable to a cyclic glycine-proline (cGP) analog of IGF-1. Cyclic glycine-proline is a naturally occurring metabolite of IGF-1 that is produced when the N-terminal tripeptide (Gly-Pro-Glu) of IGF-1 is cleaved and cyclized. This endogenous metabolite has been studied for its ability to modulate IGF-1 bioavailability and cross the blood-brain barrier.

The developers engineered NA-931 from this cyclic IGF-1 fragment scaffold to create a molecule that retains the beneficial metabolic signaling properties while achieving oral bioavailability and multi-receptor agonism. The cyclic structure provides inherent proteolytic stability that linear peptides lack, which is a key advantage for oral drug delivery.

Key Structural Features#

• Cyclic architecture: The cyclic molecular framework provides resistance to gastrointestinal proteases and peptidases, enabling oral absorption without degradation
• Lipophilicity: The molecule possesses sufficient lipophilic character to cross biological membranes, including the gastrointestinal epithelium and the blood-brain barrier
• Small molecular size: Unlike large peptide therapeutics (semaglutide at approximately 4,114 Da, tirzepatide at approximately 4,810 Da), NA-931 is a small molecule, facilitating oral absorption and tissue distribution
• No absorption enhancers required: Unlike oral semaglutide (Rybelsus), which requires co-formulation with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) to achieve approximately 0.4-1% oral bioavailability, Bioglutide achieves oral bioavailability through its inherent physicochemical properties

Pharmacokinetics#

Bioglutide exhibits pharmacokinetic properties well suited to once-daily oral dosing.

Absorption#

Bioglutide is absorbed orally without the need for absorption enhancers, special formulation technologies, or fasting requirements. Clinical data from Phase 1 and Phase 2 trials demonstrate that blood levels remain consistent regardless of whether the drug is taken in the fasting state or after a high-fat meal. This food-independent absorption is a significant practical advantage over oral semaglutide, which requires strict fasting conditions and specific water volume restrictions.

Half-Life#

The elimination half-life of Bioglutide is estimated at 16-24 hours, supporting a once-daily oral dosing regimen. This is substantially shorter than injectable GLP-1 agonists (semaglutide approximately 7 days, tirzepatide approximately 5 days) but appropriate for a daily oral medication.

Blood-Brain Barrier Penetration#

The cyclic, lipophilic structure of Bioglutide enables it to cross the blood-brain barrier. This property allows direct engagement with central appetite-regulating centers in the hypothalamus and brainstem, potentially contributing to its efficacy at relatively low doses. Most injectable GLP-1 agonists have limited direct CNS penetration and rely partly on peripheral signaling (e.g., vagal afferents) to influence central appetite regulation.

Steady-State Considerations#

With a 16-24 hour half-life and once-daily dosing, steady-state concentrations would be expected to be reached within approximately 4-5 days of initiating therapy. The relatively short half-life also means that drug washout after discontinuation would be rapid (days) compared to weekly injectable agents (weeks to months).

Receptor Pharmacology#

Bioglutide is a quadruple agonist with activity at four metabolic hormone receptors. The multi-receptor profile is unprecedented in the obesity therapeutic landscape.

IGF-1 Receptor (IGF-1R)#

IGF-1R is a receptor tyrosine kinase that mediates the anabolic effects of IGF-1, including muscle protein synthesis, cell growth, and insulin sensitization. Bioglutide's IGF-1R agonism is the most distinctive feature of its receptor profile, differentiating it from all other incretin-based obesity therapies. This activity is hypothesized to be responsible for the preservation of lean muscle mass observed in clinical trials, addressing a major limitation of existing weight loss medications.

GLP-1 Receptor (GLP-1R)#

GLP-1R is a G-protein coupled receptor (GPCR) that mediates the incretin effects of GLP-1, including glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and central appetite regulation. GLP-1R agonism is the most extensively validated mechanism for anti-obesity pharmacotherapy.

GIP Receptor (GIPR)#

GIPR is a GPCR that mediates the incretin effects of glucose-dependent insulinotropic polypeptide. GIPR agonism enhances insulin secretion, modulates lipid metabolism, and may influence adipose tissue distribution. The addition of GIPR agonism to GLP-1R agonism (as in tirzepatide) has demonstrated enhanced weight loss and glycemic control.

Glucagon Receptor (GCGR)#

GCGR is a GPCR that mediates the metabolic effects of glucagon, including hepatic glycogenolysis, gluconeogenesis, lipid oxidation, and thermogenesis. GCGR agonism can increase energy expenditure and promote fat oxidation, but must be balanced by incretin agonism to prevent hyperglycemia. Retatrutide (triple agonist) and survodutide (dual glucagon/GLP-1 agonist) also include GCGR activity.

Structural Comparison with Related Therapeutics#

Bioglutide occupies a unique position in the incretin-based therapeutic landscape as both the only quadruple agonist and the only agent in its receptor class that is a small molecule designed for oral administration.

Formulation#

Bioglutide is formulated as an oral capsule for once-daily administration. The formulation does not require absorption enhancers, enteric coatings, or other specialized drug delivery technologies. This straightforward oral formulation represents a significant practical advantage in terms of manufacturing complexity, patient convenience, and potential cost relative to pre-filled injectable pen devices or SNAC-enhanced oral formulations.

Related Reading#

• Bioglutide (NA-931) overview and research guide
• Peptides similar to Bioglutide (NA-931)
• Bioglutide (NA-931) research evidence